)
)
Cereno Scientific Investor Relations Material
Latest events
CMD 2024
Cereno Scientific
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Cereno Scientific
Access all reports
Cereno Scientific AB (publ), a clinical stage biotech company, develops therapeutics to treat cardiovascular and rare diseases through epigenetic modulation worldwide. The company is involved in developing CER-001, which is in Phase IIa study for the treatment of acute reperfused myocardial infarction; and Phase I/II study for amyotrophic lateral sclerosis patients. It has a collaboration with Oxford BioTherapeutics Ltd. to further advance the clinical development of CER-001 for the treatment of acute myocardial infarction; and strategic alliance with Novartis to develop tissue agnostic therapeutic treatments.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
CRNO
Country
🇸🇪 Sweden